Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).

被引：0
|
作者：
Bosse, Dominick
Xie, Wanling
Wells, Connor
Lalani, Aly-Khan A.
Donskov, Frede
Bent, Alisha
Sim, Hao-Wen
Beuselinck, Benoit
Bamias, Aristotelis
Porta, Camillo
Vaishampayan, Ulka N.
Pal, Sumanta K.
Agarwal, Neeraj
Srinivas, Sandy
Rini, Brian I.
Alva, Ajjai Shivaram
Wood, Lori
Kapoor, Anil
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Aarhus Univ Hosp, Aarhus, Denmark
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[6] Peter MacCallum Canc Ctr, Melbourne, Australia
[7] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, KU Leuven, Leuven, Belgium
[8] Univ Athens, Dept Clin Therapeut, Athens, Greece
[9] IRCCS San Matteo Univ Hosp Fdn, Padua, Italy
[10] Karmanos Canc Inst, Detroit, MI USA
[11] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[13] Stanford Univ, Stanford, CA USA
[14] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH USA
[15] Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI USA
[16] QEII Hlth Sci Ctr, Halifax, NS, Canada
[17] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada
[18] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e16065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16065
引用
收藏
页数：5
相关论文
共 50 条
  • [31] The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT)
    Ko, Jenny J.
    Xie, Wanling
    Heng, Daniel Yick Chin
    Kroeger, Nils
    Lee, Jae-Lyun
    Rini, Brian I.
    Knox, Jennifer J.
    Bjarnason, Georg A.
    Harshman, Lauren Christine
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Smoragiewicz, Martin
    Donskov, Frede
    Bamias, Aristotelis
    Wood, Lori
    Ernst, D. Scott
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [32] Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases
    Unnithan, J. S.
    Choueiri, T.
    Garcia, J.
    Dreicer, R.
    Laura, W.
    Bukowski, R.
    Rini, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma (Retraction of vol 10, pg 191, 2005)
    Rini, Brian
    ONCOLOGIST, 2011, 16 (10): : 1481 - 1481
  • [34] Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC).
    Vuong, Winston
    Chang, Mark
    Ruel, Nora
    Hsu, Joann
    Carmichael, Courtney
    Figlin, Robert A.
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [35] Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC)
    Vuong, Winston
    Chang, Mark
    Ruel, Nora
    Hsu, JoAnn
    Carmichael, Courtney
    Figlin, Robert A.
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
    Derosa, L.
    Guida, A.
    Albiges, L.
    Massard, C.
    Loriot, Y.
    Galli, L.
    Fizazi, K.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S478 - S479
  • [37] New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
    Derosa, L.
    Guida, A.
    Albiges, L.
    Massard, C.
    Loriot, Y.
    Biasco, E.
    Farnesi, A.
    Marconcini, R.
    Galli, L.
    Falcone, A.
    Fizazi, K.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 53 - 53
  • [38] Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience
    Matrana, Marc Ryan
    Shetty, Aditya V.
    Atkinson, Bradley J.
    Xiao, Lianchun
    Corn, Paul G.
    Millikan, Randall E.
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study
    Goebell, Peter J.
    Kube, Ulrich
    Staehler, Michael
    Doehn, Christian
    Steiner, Thomas
    Kindler, Manfred
    Herrmann, Edwin
    Janssen, Jan
    Weikert, Steffen
    Scheffler, Michael Thomas
    Schmitz, Joerg
    Overkamp, Friedrich
    Guderian, Gernot
    Albrecht, Michael
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).
    Li, Haoran
    Choueiri, Toni K.
    Wells, Connor
    Agarwal, Neeraj
    Donskov, Frede
    Lee, Jae-Lyun
    Broom, Reuben James
    Yuasa, Takeshi
    Rini, Brian I.
    Pal, Sumanta Kumar
    Wood, Lori
    Ernst, D. Scott
    Kollmannsberger, Christian K.
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Saleem, Sadia
    Beuselinck, Benoit
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345